**Friday 9 Feb 2017**

15.30-16.00: **Reception**

16.00-16.15: **Welcome and meeting objectives**

by local faculty and introduction of local faculty members

16.15-18.00: **General session 1: Diagnosis and Multimodality Treatment of Localized Disease**

Recorded sessions from ASCO GU San Francisco – selectie uit de volgende sessies:

**Christopher J. Kane, MD—Chair**
University of California, San Diego

**Thomas J. Pugh, MD—Chair**
University of Colorado

**Daniel W. Lin, MD**
University of Washington
*Welcome*

*Case-Based Debate: Magnetic Resonance and Magnetic Resonance-Directed Biopsy: Where Is the Field Moving?*

**Christopher J. Kane, MD**
University of California, San Diego
*Moderator*

**TBD**
*Radiologist*

**Caroline Moore, MD, FRCS(Urol)**
University College London
*Urologist*

**Mary-Ellen Taplin, MD**
Dana-Farber Cancer Institute
*Newly-Diagnosed High-Risk Disease Treatment: Summarizing Neoadjuvant Trials*

**Alberto Briganti, MD, PhD**
Vita-Salute San Raffaele University, Urological Research Institute, IRCCS Ospedale San Raffaele
*Adjuvant Radiotherapy and Chemotherapy in Node-Positive Disease*

*Case-Based Debate: Treating High-Risk Patients After Prostatectomy: Adjuvant Therapy Versus Early-Salvage Therapy*

**TBD**
*Moderator*

**Christopher L. Amling, MD**
Oregon Health & Science University
*Adjuvant Advocate*

**William U. Shipley, MD, FACR**
Massachusetts General Hospital, Harvard Medical School
*Early-Salvage Advocate*

*Panel Question and Answer*

18.00-18.20: **Break**

18.20-19.45: **General Session 2: Emerging Diagnostics and Therapies in Advanced Prostate Cancer**

 Recorded sessions from ASCO GU San Francisco – Selectie uit de volgende sessies:

**William L. Dahut, MD—Chair**
National Cancer Institute

**Himisha Beltran, MD—Chair**
Weill Cornell Medical College

**TBD**
*Emerging Immunotherapy Strategies for Castrate Resistant Prostate Cancer*

**Felix Feng, MD**
University of California, San Francisco
*Management of Oligometastatic Prostate Cancer From Imaging to Therapy*

**Kim N. Chi, MD, FRCPC**
British Columbia Cancer Agency
*Incorporating Genomics Into the Management of Systemic Therapy: Advances and Practicality*

**Joe M. O'Sullivan, MD, FRCR**
Queen's University Belfast
*Molecular Therapies in Bone Metastases*

*Panel Question and Answer*

19.45-20.00: Preparation of questions for live session

20.00-21.00: **Diner (first part)**

21.00-21.30: **Live connection with San Francisco**

***Topics for Q&A: oligomets & genomics + what does it mean for current daily practice?***

**Andre Bergman (NKI-AVL)**

 **Felix Feng (University of California, San Fransisco)**

 **Kim N. Chi (British Columbia Cancer Agency**

21.30: Wrap up and day 1 closure

21.40: **Dessert**

**Saturday 10 Feb 2017**

8.15-8.30: **Wrap up Friday program and preview of Saturday program**

by local faculty

8.30-9.30: **General Session 3: Moderated Debates on Controversial Topics in Prostate Cancer**

Recorded sessions from ASCO GU San Francisco – Selectie uit de volgende sessies:

**Prostate Cancer: Keynote Lecture**
**TBD**
Germline and Somatic Mutational Landscape in Prostate Cancer: State of Knowledge and Implications for Practice

**Justin E. Bekelman, MD—Chair**
Perelman School of Medicine at the University of Pennsylvania

**Francesco Montorsi, MD—Chair**
Universita Vita Salute San Raffaele

Case-Based Debate: Is There Evidence for Local Treatment in Patients with Newly Diagnosed Metastatic Disease?

**Elisabeth I. Heath, M.D.**
Barbara Ann Karmanos Cancer Institute, Wayne State University
Moderator

**Mack Roach III, MD, FASCO**
University of California, San Francisco
Advocate

**Adam Dicker, MD, PhD**
Sidney Kimmel Cancer Center
Skeptic

Case-Based Debate: Abiraterone Versus Docetaxel

**Nicholas J. Van As, FRCR**
The Royal Marsden NHS Foundation Trust
Moderator

**Karim Fizazi, MD, PhD**
Gustave Roussy, University of Paris Sud
Abiraterone Advocate

**Christopher Sweeney, MBBS**
Dana-Farber Cancer Institute
Docetaxel Advocate

Panel Question and Answer

9.30-9.45: Case discussion (own casus of faculty)

9.45-10.15: Selected poster sessions (Poster presenters interviews)

10.15-10.30: **Break**

10.30-12.00: **General Session 4: Current and Future Directions of Muscle-Invasive Bladder Cancer**

Recorded sessions from ASCO GU San Francisco- selectie uit de volgende sessies:

**Jeanny B. Aragon-Ching, MD, FACP—Chair**
Inova Schar Cancer Institute

**Nicholas J. Van As, FRCR—Chair**
The Royal Marsden NHS Foundation Trust

**Jeffrey M. Holzbeierlein, MD, FACS**
 University of Kansas Health System
Welcome and Lessons Learned From New Guidelines and How They Have Changed Management of Muscle-Invasive Bladder Cancer

**Peter C. Black, MD**
University of British Columbia
Selective Versus Nonselective Use of Neoadjuvant Chemotherapy: Use of Molecular Markers for Identifying Patients and Therapies

**Peter Hoskin, MD, FRCP, FRCR**
Mount Vernon Cancer Centre
Use of Molecular Markers in Bladder Preservation Therapy

**Abhishek A. Solanki, MD, MS**
Loyola University Chicago
Role of Immunotherapy in Patients Undergoing Radiation Therapy for Bladder Cancer

Panel Question and Answer

12.00-12.15: Case discussion (own casus of faculty)

12.15-13.00: **Lunch**

13.00-14.30: **General Session 5: Multimodality Approach to Locally Advanced Bladder Cancer (ARS)**

Recorded sessions from ASCO GU San Francisco- selectie uit de volgende sessies:

**Ananya Choudhury, MA, PhD, MRCP, FRCR—Chair**
The Christie NHS Foundation Trust and University of Manchester

**Yair Lotan, MD—Chair**
The University of Texas Southwestern Medical Center

Case Panel Discussion

**Alison J. Birtle, MRCP, FRCR, MD**
Lancashire Teaching Hospitals NHS Trust
Radiation Oncologist

**Alfred Witjes, MD, PhD**
Radboud University Nijmegen Medical Centre
Urologist

**Dean F. Bajorin, MD, FACP, FASCO**
Memorial Sloan-Kettering Cancer Center
Medical Oncologist

Panel Question and Answer

14.30-14.45: **Break**

14.45-15.30: **Recorded session with questions by Dutch participants**

 **Alison J. Birtle (Lancashire Teaching Hospitals NHS Trust)**

**Dean F. Bajorin (Memorial Sloan-Kettering Cancer Center)**

**Fred Witjes (Radboud University Nijmegen Medical Centre) (moderator /interviewer)**

topic: bladder preservation and modalities including immunotherapy

15.30-16.00: **Meeting close & wrap up**

 By local faculty